The studies evaluated routine clinical practice data from more than 800 hospitals in the US.
Your search for supplemental oxygen returned 8 results
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
Kineret is an interleukin-1 receptor antagonist.
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Findings showed that the trial did not meet statistical significance on the primary endpoint.